Transformational cell therapies for patients with pancreatic disease

OUR PIPELINE OF CELL THERAPIES IS CHANGING THE OUTLOOK FOR PATIENTS WITH CHRONIC PANCREATITIS AND TYPE 1 DIABETES.

Matthew Lehman,

Chief Executive Officer (Koligo Therapeutics Inc.) and Executive Director

Proven biotech & cell therapy executive
NASDAQ-listed Prima Biomed, CSE-listed M Pharmaceutical, private CRO SPRI Clinical Trials
Clinical research & manufacturing scale-up expertise
MS Columbia; BA Louisville

Stuart Williams, PhD,

Chief Technology Officer (Koligo Therapeutics Inc.) and Executive Director

Division chief, Bioficial Heart, Cardiovascular Innovation Institude
300+ publications & 16 issued US patents in cell & tissue engineering
Experienced academic-industry partner: founded three biotech companies
PhD cell biology University of Delaware, postdoc Yale School of Medicine

Peter James,

Non-Executive Director

30+ years’ experience in emerging technologies
Extensive experience as Chair, Non-Executive Director and CEO of both publicly listed and private companies

Jethro Marks,

Non-Executive Director

Co-founder and CEO of The Nile and Mercury Retail, a leading Australian eCommerce service provider
15+ years’ experience in marketing

Robert Clisdell,

Non-Executive Director

Head of Bergen Capital LLC Australian office
Extensive experience as director for publicly traded corporations
15+ years’ experience in banking, finance and accounting as an investment banker with Credit Suisse and Caliburn Partnership
Graduate Diploma in Applied Finance and Investment from FINSIA

Kyslecel personalized cell therapy for chronic pancreatitis. Because pain should not define your life.